Table 1. FDA-approved radiopharmaceuticals targeting PSMA/SSTR for imaging/therapy.

Radiopharmaceutical name	Brand name	Effect	Tumor type	Target molecule	Approved date	Indications and usage
PSMA, prostate specific membrane antigen; SSTR, somatostatin receptor; PCa, prostate cancer; NET, neuroendocrine tumor; mCRPC, metastatic castration-resistant prostate cancer; PET, positron emission tomography.
Fluorine-18 flotufolast	POSLUMA	Imaging	PCa	PSMA	2023.05.25	To identify suspected metastasis or recurrence of prostate cancer
Gallium-68 Gozetotide	Locametz Illuccix	Imaging	PCa	PSMA	2022.03.23	To identify suspected metastasis or recurrence of prostate cancer
Fluorine-18 piflufolastat	Pylarify	Imaging	PCa	PSMA	2021.05.27	To identify suspected metastasis or recurrence of prostate cancer
Gallium-68 PSMA-11	−	Imaging	PCa	PSMA	2020.12.01	To identify suspected metastasis or recurrence of prostate cancer
Lutetium-177 PSMA-617	Pluvicto	Therapy	PCa	PSMA	2022.03.23	Treatment of PSMA-positive mCRPC adult patients who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy
Copper-64 dotatate	Detectnet	Imaging	NETs	SSTR	2020.09.03	Localization of SSTR-positive NETs in adult patients using PET
Gallium-68 dotatoc	−	Imaging	NETs	SSTR	2019.08.22	Localization of SSTR-positive NETs in adult and pediatric patients using PET
Gallium-68 dotatate	NETSPOT	Imaging	NETs	SSTR	2016.06.01	Localization of SSTR-positive NETs in adult and pediatric patients using PET
Lutetium-177 dotatate	LUTATHERA	Therapy	NETs	SSTR	2018.01.26	Treatment of SSTR-positive NETs of gastroenteropancreatic origin, including foregut, midgut, and hindgut NETs